ArticleBioinformation2024
Clinical characterization, molecular and genomic sequencing analysis of SARS-Cov-2 during second wave at Raigarh, Chhattisgarh, India.
Article in Bioinformation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The severe acute respiratory syndrome coronavirus-2 (SARS-Cov-2) has been changing continuously. This study was conducted to evaluate clinical characteristics, Molecular analysis & Genomic sequencing of SARS-Cov-2 during second wave in Raigarh district, Chhattisgarh, India. This study evaluated 13402 breakthrough cases of COVID -19. The laboratory obtained the nasopharyngeal/oropharyngeal swabs (NPS/OPS) of SARS-CoV-2 patients who tested positive by real-time RT-PCR, together with clinical and demographic information. Next generation sequencing (NGS) was used to sequence these clinical specimens in order to identify nucleotide changes in the SARS-CoV-2 genome from these strains. In the study population, variants of concern (VOCs) and other variations were looked for. Clinical severity was mild in 47.05% patients with mutational variants; while 52.94% patient's clinical severity was moderate. Delta (B.1.617.2) was the most common VOC detected. Among non VOC variants, AY.4 and AY.12 variants were most commonly detected. Envelope (E) gene and RNA-dependent RNA polymerase (RdRp) mutation were most commonly observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.